NOV 2 0 2007 W Express Mail Labe No. EM015925413US

Typed or printed name

11-23-07

6

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	Application Number	10/570,117		
TRANSMITTAL	Filing Date	February 28, 2006		
FORM	First Named Inventor	Joerg Heyer		
,	Art Unit	Not Yet Assigned		
(to be used for all correspondence after initial filing)	Examiner Name	Not Yet Assigned		
Total Number of Pages in This Submission	Attorney Docket Number	GEN/022		

ENCLOSURES (Check all that apply)								
Fee Transr	mittal Form	Drawing(s)		After Allowance Communication to TC				
Fee /	Attached	Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences				
Amendmer	nt/Reply	Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)				
After	Final	Petition to Convert to a Provisional Application		Proprietary Information				
Affida	avits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address		Status Letter				
Extension	of Time Request	Terminal Disclaimer		Other Enclosure(s) (please Identify below):				
Express Al	pandonment Request	Request for Refund		Postcard				
Information	Disclosure Statement	CD, Number of CD(s) Landscape Table on CD						
PTO/SB/08 With 21 cite	D/SB/08a (in duplicate) 121 cited references Remarks							
Response	Response to Missing Parts/ The Director is hereby authorized to charge payment of any additional fees							
Incomplete Application required in connection with this Information Disclosure Statement to Deposit								
Response to Missing Parts under 37 CFR 1.52 or 1.53 Account No. 06-1075, Order No. 001581-0211. A duplicate copy of is transmitted herewith.			211. A duplicate copy of this letter					
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT								
Firm Name	Ropes & Gray LLP (Cus	stomer No. 1473)						
Signature Connie Word								
Printed name Connie Wong								
Date	November 20, 2007		g. No.	L0104				
EXPRESS MAIL CERTIFICATION (EM015925413US)								
I hereby certify that this paper/fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO								
ADDRESSEE" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Mail Stop Amendment, Hon. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.								
Signature And Sahle								

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Schlie

arah

November 20, 2007

Date

E Mail Lah	oi No. EMO45005440U				•			
2 0 2007 When the Pa	pel No. EM015925413U	o persons	U.S. Patent and are required to respond to a collection of	Appro Tradem	PTO/SB/21 (09-04) ved for use through 07/31/2006. OMB 0651-0031 ark Office; U.S. DEPARTMENT OF COMMERCE on unless it displays a valid OMB control number.			
/ <u>Q</u> /			Application Number		570,117			
TRANSMITTAL FORM		Filing Date	_	ruary 28, 2006				
		First Named Inventor		rg Heyer				
		Art Unit		Yet Assigned				
(to be used for a	ll correspondence after initial filin	g)	Examiner Name		Yet Assigned			
	ges in This Submission		Attorney Docket Number		1/022			
		ENCLO	SURES (Check all that apply)					
Fee Transmitta	l Form	D	rawing(s)		After Allowance Communication to TC			
Fee Attac	ched	Li-	censing-related Papers		Appeal Communication to Board of Appeals and Interferences			
Amendment/Re	ply	D Pé	etition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)			
After Fina	ıt [Pr	etition to Convert to a ovisional Application		Proprietary Information			
Affidavits/	declaration(s)	☐ Po	ower of Attorney, Revocation nange of Correspondence Address		Status Letter			
Extension of Tir	ne Request		eminal Disclaimer	\boxtimes	Other Enclosure(s) (please Identify below):			
Express Abando	onment Request	Re	equest for Refund		Postcard			
Information Disc	closure Statement), Number of CD(s)					
PTO/SB/08a (in With 21 cited ref	PTO/SB/08a (in duplicate) With 21 cited references		Landscape Table on CD Remarks					
Response to Mi				haraa	payment of any additional face			
Incomplete Application required in con			in connection with this Inform	or is hereby authorized to charge payment of any additional fees connection with this Information Disclosure Statement to Deposit				
	Response to Missing Parts ACCOUNT NO. 06-1075,			81-02	11. A duplicate copy of this letter			
under 37 CI	under 37 CFR 1.52 or 1.53 is transmitted herewith.							
								
Cim Nama			APPLICANT, ATTORNEY, OF	RAGE	ENT			
Firm Name Ropes & Gray LLP (Customer No. 1473)								
Signature	onnie Warf							
Date Nov	vember 20, 2007		Reg	No.	L0104			
EXPRESS MAIL CERTIFICATION (EM015925413US)								
I hereby certify that this paper/fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Mail Stop Amendment, Hon. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.								
Signature	Signature Sarah Sable							
Typed or printed name Sarah Schlie Date November 20, 20					Date November 20, 2007			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date November 20, 2007

Attorney Docket No.: GEN/022

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Joerg Heyer et al.

Application No.

10/570,117

Confirmation No.:

8044

Filed

February 28, 2006

For

TUMOR-SPECIFIC EXPRESSION OF REPORTER GENES

Group Art Unit

Not Yet Assigned

Examiner

Not Yet Assigned

New York, New York November 20, 2007

Mail Stop: Amendment Hon. Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants, through their attorneys, make of record the documents listed below. Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), applicants have not provided paper copies of the U.S. Patent Documents, which are listed on the accompanying Form PTO/SB/08A (submitted in duplicate).

Applicants respectfully request that the documents listed below and on Form PTO/SB/08A be (1) fully considered by the Examiner prior to issuance of any patent from this application and (2) printed on any patent issuing from this application.

Applicants also request that a copy of the enclosed Form PTO/SB/08A duly initialed by the Examiner be forwarded to the undersigned with the next communication.

Other Documents

Bao, R., et al., "Activation of cancer-specific gene expression by the survivin promoter," J. of the National Cancer Inst. 94:522-528 (2002).

Chatterjee, B., et al., "BMP regulation of the mouse connexin43 promoter in osteoblastic cells and embryos," Cell Communication and Adhesion 10:37-50 (2003).

Contag, et al., "Advances in in vivo bioluminescence imaging of gene expression," Annual Review of Biomed. Eng. 4:235-260 (2002).

Coralli, C., et al., "Limitations of the reporter green fluorescent protein under simulated tumor conditions," Cancer Research 61:4784-4790 (2001).

Elbashir et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," *Methods* 26:199-213 (2002).

Giles et al., "Caught up in a Wnt storm: Wnt signaling in cancer," Biochimica et Biophysica Acta 1653:1-24 (2003).

Hannon, "RNA interference," Nature 418:244-251 (2002).

Jacks et al., "Effects of an Rb mutation in the mouse," Nature 359:295-300 (1992).

Kim et al., "Survivin and molecular pathogenesis of colorectal cancer," Lancet 362:205-209 (2003).

Massuda, E.S., et al., "Regulated expression of the diphtheria toxin A chain by a tumor-specific chimeric transcription factor results in selective toxicity for alveolar rhabdomyosarcoma cells," *Proc. Nat'l. Acad. Sci.* 94:14701-14706 (1997).

McManus, M.T., et al., "Gene silencing in mammals by small interfering RNAs," Nature Reviews 3:737-747 (2002).

Staal, F.J.T., et al., "Tcf-1-mediated transcription in T lymphocytes: differential role for glycogen synthase kinase-3 in fibroblasts and T cells," *Int'l Immunology* 11:317-323 (1999).

Vooijs et al., "Noninbasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice," Cancer Res. 62(6):1862-1867 (2002).

Young, M.R. et al., "Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion," *Proc. Natl. Acad. Sci.* 96:9827-9832 (1999).

Zhong, S., et al., "Organ-specific activation of acitvator protein-1 in transgenic mice by 12-O-tetradecanoylphorbol-13-acetate with different administration methods," Cancer Research 61:4084-4091 (2001).

Zhong, S.P., et al., "Organ-specific distribution of AP-1 in AP-1 luciferase transgenic mice during the maturation process," Am. J. Physiol Regul Integr Comp Physiol 280:R376-R381 (2001).

This Statement is being submitted more than three months from the application filing date but before the mailing date of the first Office Action on the merits.

In accordance with 37 C.F.R. § 1.97, submission of this Statement requires no fee.

The Director, however, is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075, Order No. 001581-0211.

Respectfully submitted,

Jane T. Gunnison (Reg. No. 38,479)

Connie Wong (Reg. No. L0104)

Connewons

Attorneys for Applicants

ROPES & GRAY LLP

Customer No. 1473

1211Avenue of the Americas New York, New York 10036

Tel.: (212) 596-9000

Fax.: (212) 596-9090



Attorney Docket No.: GEN/022

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Joerg Heyer et al.

Application No.

10/570,117

Confirmation No.:

8044

Filed

February 28, 2006

For

TUMOR-SPECIFIC EXPRESSION OF REPORTER GENES

Group Art Unit

Not Yet Assigned

Examiner

Not Yet Assigned

New York, New York November 20, 2007

Mail Stop: Amendment Hon. Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

<u>INFORMATION DISCLOSURE STATEMENT</u>

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants, through their attorneys, make of record the documents listed below. Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), applicants have not provided paper copies of the U.S. Patent Documents, which are listed on the accompanying Form PTO/SB/08A (submitted in duplicate).

Applicants respectfully request that the documents listed below and on Form PTO/SB/08A be (1) fully considered by the Examiner prior to issuance of any patent from this application and (2) printed on any patent issuing from this application.

Applicants also request that a copy of the enclosed Form PTO/SB/08A duly initialed by the Examiner be forwarded to the undersigned with the next communication.

Other Documents

Bao, R., et al., "Activation of cancer-specific gene expression by the survivin promoter," J. of the National Cancer Inst. 94:522-528 (2002).

Chatterjee, B., et al., "BMP regulation of the mouse connexin43 promoter in osteoblastic cells and embryos," Cell Communication and Adhesion 10:37-50 (2003).

Contag, et al., "Advances in in vivo bioluminescence imaging of gene expression," Annual Review of Biomed. Eng. 4:235-260 (2002).

Coralli, C., et al., "Limitations of the reporter green fluorescent protein under simulated tumor conditions," Cancer Research 61:4784-4790 (2001).

Elbashir et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," Methods 26:199-213 (2002).

Giles et al., "Caught up in a Wnt storm: Wnt signaling in cancer," Biochimica et Biophysica Acta 1653:1-24 (2003).

Hannon, "RNA interference," Nature 418:244-251 (2002).

Jacks et al., "Effects of an Rb mutation in the mouse," Nature 359:295-300 (1992).

Kim et al., "Survivin and molecular pathogenesis of colorectal cancer," Lancet 362:205-209 (2003).

Massuda, E.S., et al., "Regulated expression of the diphtheria toxin A chain by a tumor-specific chimeric transcription factor results in selective toxicity for alveolar rhabdomyosarcoma cells," *Proc. Nat'l. Acad. Sci.* 94:14701-14706 (1997).

McManus, M.T., et al., "Gene silencing in mammals by small interfering RNAs," *Nature Reviews* 3:737-747 (2002).

Staal, F.J.T., et al., "Tcf-1-mediated transcription in T lymphocytes: differential role for glycogen synthase kinase-3 in fibroblasts and T cells," *Int'l Immunology* 11:317-323 (1999).

Vooijs et al., "Noninbasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice," Cancer Res. 62(6):1862-1867 (2002).

Young, M.R. et al., "Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion," *Proc. Natl. Acad. Sci.* 96:9827-9832 (1999).

Zhong, S., et al., "Organ-specific activation of acitvator protein-1 in transgenic mice by 12-O-tetradecanoylphorbol-13-acetate with different administration methods," Cancer Research 61:4084-4091 (2001).

Zhong, S.P., et al., "Organ-specific distribution of AP-1 in AP-1 luciferase transgenic mice during the maturation process," Am. J. Physiol Regul Integr Comp Physiol 280:R376-R381 (2001).

This Statement is being submitted more than three months from the application filing date but before the mailing date of the first Office Action on the merits. In accordance with 37 C.F.R. § 1.97, submission of this Statement requires no fee.

The Director, however, is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075, Order No. 001581-0211.

Respectfully submitted,

Jane T. Gunnison (Reg. No. 38,479)

Connie Wong (Reg. No. L0104)

Connewons

Attorneys for Applicants

ROPES & GRAY LLP

Customer No. 1473

1211Avenue of the Americas

New York, New York 10036

Tel.: (212) 596-9000 Fax.: (212) 596-9090